Infectious Disease Assay Development Core

项目摘要 传染病检测开发实验室（IDAD），用于研究传染病的化学生物学 Disease提供了有关测定开发和小分子文库筛选的专业知识。化合物 作为化学工具或探针用于解剖作用机制， 调节传染病靶标。除了提供物质和技术资源， 进行化学筛选时，设计、开发和优化真正反映特定 传染病生物学中的靶功能。堪萨斯大学有一个成熟和成功的HTS 拥有优秀的智力和体力资源的设施。传染病检测开发核心 在CBID第一阶段建立的资金利用了这些资产，并扩展了现有的能力 通过提供额外的专业知识和专门的研究空间来开发针对新疾病的检测方法， 相关目标。该中心的总体目标是提供一整套专业知识、设施、服务， HTS检测设计、开发、验证、小规模和大规模筛选领域的培训， 基于生物体（细胞）或生物化学的传染病靶标。这些努力的预期成果是 适合于自动化大规模筛选的小型化和经验证的测定， 内部或外部。这些专门知识和资源还将使调查人员能够开发 响应发现化学探针的资助机会公告的竞争性提案，或 美国国防部或NIH的治疗药物。此外，通过成功的 分析开发和小分子筛选工作是计算 化学生物学和合成化学生物学的核心成功开发优化 用作化学探针和感染性疾病的预治疗剂的化合物。

PROJECT SUMMARY The Infectious Disease Assay Development (IDAD) laboratory for studying the Chemical Biology of Infectious Disease provides expertise on assay development and screening of small molecule libraries. The compounds identified from the screen serve as chemical tools or probes for dissecting mechanism of action and modulating infectious disease targets. In addition to the availability of physical and technical resources to perform chemical screening, it is critical to design, develop and optimize assays that truly reflect specific target function in infectious disease biology. The University of Kansas has an established and successful HTS facility with excellent intellectual and physical resources. The Infectious Disease Assay Development core established in Phase I of CBID funding takes advantage of these assets and expands the current capabilities by providing additional expertise and dedicated research space to develop assays against novel disease relevant targets. The overall goal of this core is to provide a full array of expertise, facilities, services, and training in the area of HTS assay design, development, validation, small and large-scale screening for organism (cell) based or biochemical infectious disease targets. The expected outcomes of these efforts are miniaturized and validated assays suitable for automated large-scale screening that can be performed internally or externally. The expertise and resources are also expected to enable investigators to develop competitive proposals in response to funding opportunity announcements for discovery of chemical probes or therapeutic agents from Department of Defense, or NIH. Additionally, hits generated through successful assay development and small molecule screening efforts serve as starting points for the Computational Chemical Biology and the Synthetic Chemical Biology cores for successful development of optimized compounds for use as chemical probes and pre-therapeutics for infectious diseases.